AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02598219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-operative SN mapping with patent V blue dye
Description: 1. Patent blue V dye are diluted with saline sterile solution to obtain 4ml of 50%. Four 1ml syringe, each containing a 50% patent blue dye solution, are prepared per patient.~2. Intracervical injection is performed by the surgeon. after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible.~3. SN are detected by direct visualization of blue colored lymphatics and node
Study NCT02598219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-operative SN mapping with indocyanin green
Description: 1: Infracyanine powder is diluted in aqueous sterile water to obtain 4ml with a concentration of 1.25 mg/mL. Four 1ml syringe, each containing a 1.25 mg/mL Infracyanine dye solution, are prepared per patient.~2- Intracervical injection is performed by the surgeon, after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible~3- SN detection by near-infrared fluorescence imaging
Study NCT02598219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full bilateral laparoscopic lymphadenectomy and Hysterectomy
Description: * Bilateral pelvic lymphadenectomy (intermediate risk endometrioid)~* Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid)~* Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)
Study NCT02598219 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Current initial staging protocols
Description: Current French initial staging protocols
Study NCT04458922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT04458922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Correlative studies
Study NCT04458922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT04458922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT03534323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells.
Study NCT03534323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax targets a protein called BCL-2, which helps cancer cells survive.
Study NCT04404114 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Shear wave elastography to distinguish AKI from normal kidney
Description: Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
Study NCT04404114 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Shear wave elastography to distinguish AKI from CKD
Description: Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
Study NCT04404114 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Shear wave elastography to distinguish CKD from normal kidney
Description: Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
Study NCT03344549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Renal nutrition teleconsultation
Description: Renal Nutritional teleconsultation for patients with diabetic kidney disease without dialysis, monthly for 4 months.
Study NCT03344549 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Face-to-face consultation of renal nutrition
Description: Face-to-face consultation of renal nutrition for patients with diabetic kidney disease without dialysis, monthly for 4 months.
Study NCT03340129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab 3mg per kg every 3 weeks for 4 doses
Study NCT03340129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab 1mg/kg every 3 weeks for 4 doses, then 480mg every 4 weeks.
Study NCT03340129 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiotherapy
Description: The first dose of immunotherapy Must be given prior to the start of radiotherapy. One fraction at between 16 to 22 Gy or 24 to 30 Gy hypofractionated for larger lesions.
Study NCT03340129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salvage therapy
Description: Any form of salvage therapy (surgery or radiotherapy) for intracranial disease progression, further disease control at any site, symptom control or treatment of cerebral haemorrhage or cerebral radionecrosis.
Study NCT00762138 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AutoloGel System
Description: The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a week for eight (8) weeks. The treating health care practitioner may elect to continue the treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with standard of care procedures for comprehensive wound management , such as:~Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment Management of wound infection Wound cleansing Nutritional support, including blood glucose control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure ulcers at risk for contamination Management of underlying disease
Study NCT03819556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk protein in fresh milk
Description: Milk protein in increasing doses.
Study NCT04518852 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TACE combined with sorafenib and PD-1 mAb
Description: the combination of local therapy (TACE), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
Study NCT01710943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Cognitive Behavioral Treatment
Description: Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. We expect that each session will be approximately 30 minutes in duration. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial. They can choose to do this using a designated computer in a private room at their local VA or can complete these sessions in the privacy of their own home with their personally-owned computers. Participants can choose to complete each session on any day/time of their choosing in a given week.
Study NCT00599391 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Far Infrared Radiation for 30 to 40 minutes per session.
Study NCT01165320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Study NCT00453115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 85mg/m2 iv on D1 and 15, every 4 weeks until disease progression
Study NCT00453115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1250mg/m2 iv on day 1 and 15, every 4 weeks until disease progression
Study NCT02019446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Treatment YAG laser
Description: YAG Laser / FOX Laser
Study NCT02019446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment (control group) terbinafine hydrochloride tablets
Description: Terbinafine hydrochloride tablets tablets
Study NCT02210689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin phosphate vaginal cream 2%
Study NCT02210689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clindamycin phosphate vaginal cream 2%
Study NCT02210689 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: vehicle used as placebo
Study NCT02365467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Mona LSA Thoracic Stent Graft System
Study NCT02829281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Joint injection of Saline
Study NCT01553149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01553149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03666897 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DTI Images and Plasma Biomarkers
Description: Additional Images added from standard of care MRI, Bio-markers identified
Study NCT01689870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-OX40
Description: Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5
Study NCT01689870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1
Study NCT00508625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 951 (rhApo2L/TRAIL)
Description: AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).
Study NCT00508625 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).
Study NCT00508625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).
Study NCT00508625 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Standard platinum based chemotherapy
Study NCT00508625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard platinum based chemotherapy
Study NCT00508625 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Standard taxane chemotherapy
Study NCT00508625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard taxane chemotherapy
Study NCT04319120 — intervention group
Intervention type: OTHER
Intervention: questionnaires online
Description: Each month, the nurse will contact the patients included, by mail or telephone, to fill out their questionnaires online or by mail, and to make a photo of the ulcer if it is healed. A dedicated telephone line and e-mail address will be used as a support if necessary (for questionnaires, emails or sending photos). The referring nurse and the clinical research assistant of the service will be in charge of centralizing the data collected.
Study NCT01269060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Incision Laparoscopic Surgery
Description: Single Incision Laparoscopic Sigmoidectomy
Study NCT02539277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jinyebaidu granule
Description: It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.
Study NCT02539277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fufangshuanghua granule
Description: It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.
Study NCT02539277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jinyebaidu granule placebo
Description: It is Jinyebaidu granule placebo.
Study NCT02539277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fufangshuanghua granule placebo
Description: It is Fufangshuanghua granule placebo.
Study NCT01060930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of L-NMMA and Nor-epinephrine
Description: Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
Study NCT01389921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials
Study NCT01389921 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalography
Description: Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials
Study NCT01211106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: Although almost every form of psychotherapy has been advocated for PTSD, all evidence-based psychotherapies for PTSD are CBT programs that include variants of exposure therapy (Prolonged Exposure), cognitive therapy (CT), stress inoculation training (SIT), eye movement desensitization and reprocessing (EMDR), or combinations of these procedures. Exposure therapy involves helping PTSD sufferers to gradually confront distressing trauma-related memories and reminders to facilitate successful emotional processing of the trauma memory and reduction of associated distress. Most exposure therapy programs include both imaginable confrontation with the traumatic memories and in vivo exposure to trauma reminders.
Study NCT01211106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: Motivational Interviewing (MI) is defined as a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. MI is characterized by its spirit, which is defined as collaboration with the client, evocation of the client's own perceptions, goals, and values, and respect for the client's autonomy.
Study NCT02906657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication reconciliation
Description: The medication reconciliation list will be compared to the drugs prescribed by the hospital physician at admission and discrepancies will be analyzed by discussion between the physician and the pharmacist
Study NCT02945059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective reversible portal vein embolization
Description: Percutaneous access to the portal vein is achieved under general anesthesia with ultrasound or fluoroscopic control. After assessment of portal venous anatomy, embolization of selected portal vein segments is performed using the powdered form of an absorbable gelatin sponge.
Study NCT00084435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 IV, Day 1, q 21 days for 3 cycles
Study NCT00084435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 15 mg/m2 IV, Day 1, 1 7 days for 6 doses
Study NCT00084435 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 200 cGy/day, Days 1-5, q week for 6 weeks
Study NCT00357994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa carbidopa intestinal gel (LCIG)
Description: infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
Study NCT00357994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo gel
Study NCT00357994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets
Study NCT00357994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PBO) oral capsules
Study NCT00357994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy® 1400 ambulatory infusion pump
Study NCT00357994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CADD-Legacy® 1400 ambulatory infusion pump
Study NCT00357994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEG tube
Description: percutaneous endoscopic gastrostomy tube
Study NCT00357994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEG tube
Description: percutaneous endoscopic gastrostomy tube
Study NCT00357994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-tube
Description: jejunal tube
Study NCT00357994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: J-tube
Description: jejunal tube
Study NCT01946594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Study NCT01946594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01911156 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Continue NA treatment
Description: Prescribed NA during the 72 week study period
Study NCT01911156 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Discontinue NA Treatment
Description: Discontinue NA Treatment
Study NCT03658915 — intervention group
Intervention type: DEVICE
Intervention: Smartphone application (Goniometer Pro )
Description: Knee repositioning error will be measured simultaneously by smartphone and Biodex isokinetic dynamometer by a single blind assessor. All assessments will be done with eyes closed and repeated over two separate sessions, with one-week interval in-between. For active repositioning, the participant will actively extend the knee to reach a predetermined target position45° flexion at an angular velocity of 10°/sec. For passive knee repositioning, the isokinetic dynamometer will move the knee at 5°/s to a predetermined angle between 5° and 80° of flexion and the participant should stop the movement when the predetermined angle is reached.
Study NCT00692913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)
Description: FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
Study NCT00692913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Supplement 500 mg
Description: Calcium supplied locally by the investigator (containing 500 mg~calcium supplement) daily for 52 weeks (unless the patient's dietary intake of~calcium exceeds 1000 mg per day).
Study NCT00692913 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Referred-Care Model
Description: Usual treatment for osteoporosis chosen and prescribed by patients' own physicians for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
Study NCT00477282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karenitecin
Description: Karenitecin 1.0mg/m2/day administered as a single daily IV infusion over 60 minutes for 5 consecutive days every 3 weeks (21 days)
Study NCT00477282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan 1.5 mg/m2/day administered as a single daily IV infusion over 30 minutes for 5 consecutive days every 3 weeks (21 days)
Study NCT03929575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of calcium
Description: Ingestion of 250 mg of calcium
Study NCT03929575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rhodiola
Description: Ingestion of 250 mg of Rhodiola
Study NCT03442777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allevyn® brand silicone adhesive multilayer foam dressings
Description: Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith\&Nephew (Allevyn® brand).
Study NCT03442777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex® brand silicone adhesive multilayer foam dressings
Description: Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).
Study NCT05304624 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser
Description: these lasers are routinely used in dental practice
Study NCT05304624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser
Description: these lasers are routinely used in dental practice